about
A novel flow cytometric HTS assay reveals functional modulators of ATP binding cassette transporter ABCB6A crowdsourcing evaluation of the NIH chemical probesOf possible cheminformatics futures.High-throughput screening with HyperCyt flow cytometry to detect small molecule formylpeptide receptor ligands.Lead-like, drug-like or "Pub-like": how different are they?Duplex high-throughput flow cytometry screen identifies two novel formylpeptide receptor family probes.Detection of intracellular granularity induction in prostate cancer cell lines by small molecules using the HyperCyt high-throughput flow cytometry system.Structural simplification of bioactive natural products with multicomponent synthesis. 3. Fused uracil-containing heterocycles as novel topoisomerase-targeting agentsHigh-throughput screen for the chemical inhibitors of antiapoptotic bcl-2 family proteins by multiplex flow cytometry.A high throughput flow cytometric assay platform targeting transporter inhibitionHighly efficient synthesis and characterization of the GPR30-selective agonist G-1 and related tetrahydroquinoline analogs.Microbial efflux pump inhibition: tactics and strategies.Cheminformatics aspects of high throughput screening: from robots to models: symposium summaryA selective ATP-binding cassette subfamily G member 2 efflux inhibitor revealed via high-throughput flow cytometry.Fluorescent substrates for flow cytometric evaluation of efflux inhibition in ABCB1, ABCC1, and ABCG2 transporters.FRET detection of lymphocyte function-associated antigen-1 conformational extension.Exploring the biological promiscuity of high-throughput screening hits through DFT calculations.Ligand-directed targeting of lymphatic vessels uncovers mechanistic insights in melanoma metastasisLigand-directed profiling of organelles with internalizing phage libraries.Identification of a GPER/GPR30 antagonist with improved estrogen receptor counterselectivityAssociating Drugs, Targets and Clinical Outcomes into an Integrated Network Affords a New Platform for Computer-Aided Drug Repurposing.Drug Repurposing from an Academic Perspective.Identification of a small molecule yeast TORC1 inhibitor with a multiplex screen based on flow cytometryStrategies for compound selection.The CARLSBAD database: a confederated database of chemical bioactivitiesEmerging trends in the discovery of natural product antibacterials.Therapeutic options and emerging alternatives for multidrug resistant staphylococcal infections.Real-time analysis of conformation-sensitive antibody binding provides new insights into integrin conformational regulation.Modulation of bitter taste perception by a small molecule hTAS2R antagonistDefining the microbial effluxome in the content of the host-microbiome interactionSignificance of MTD and other descriptors in lipophilicity models for chlorinated aromatic compounds.Quantitative structure-activity relationship by CoMFA for cyclic urea and nonpeptide-cyclic cyanoguanidine derivatives on wild type and mutant HIV-1 protease.Dissociation of I domain and global conformational changes in LFA-1: refinement of small molecule-I domain structure-activity relationships.Post-high-throughput screening analysis: an empirical compound prioritization scheme.Integration of virtual screening with high-throughput flow cytometry to identify novel small molecule formylpeptide receptor antagonists.Virtual and biomolecular screening converge on a selective agonist for GPR30.High-throughput flow cytometry for drug discovery.Descriptor collision and confusion: toward the design of descriptors to mask chemical structures.An automated PLS search for biologically relevant QSAR descriptors.Chemical database preparation for compound acquisition or virtual screening.
P50
Q28481236-B85D1EF2-08FF-451A-A18E-56C3E5116EB3Q28842738-47220706-BE5A-4D1E-A2A8-C7172D4AE61CQ30485257-FF162DE7-9FCD-45AA-B107-036A4BEB1E3EQ33217398-A27A1DC9-49DB-4C0D-B25E-8C84EE739924Q33276455-15F61838-796E-423F-B507-270D269098B2Q33368728-09503D29-4D23-4F63-B701-21E4C33CEECAQ33453105-B1B52180-9C66-434F-9CCA-35313B087175Q33841304-1B0A2D0C-6C31-4102-AC8F-A10CBC71FE1CQ33895708-A0330EF6-4FB4-42D9-BBD0-7A40711E2046Q33912745-29C37401-9205-40B2-96EF-1F4CA182E4A0Q34033184-A7B3C3DB-6966-4F69-9FBA-D7996DEFC0FCQ34176211-2A0D1066-E749-4E7C-87AA-176FE0378592Q34380828-2E0D974D-CB5B-44B2-BF93-4A3B9D880997Q34393952-A8D92E07-28EF-4D5D-B498-8DAAE658A20DQ34613849-461E0EF4-2A1C-4EE3-BF85-25BB6AB3D8B3Q34786041-5F8BB9CD-FF5D-4172-838E-639E28A1D7F4Q35127647-7C2647B4-2B9C-4E28-9BB9-0A70F2E4B991Q35134617-E860BAA7-8550-4DA1-9A62-C302AA184730Q35553061-E6681516-D8B2-4766-8F9C-0AEED3E6F389Q35563456-5E33146A-3484-40E6-9480-106A5869F4E5Q35694643-2FECEF4E-4D34-4F80-BC58-AC41D3E39A4CQ35774211-AB3EFA4D-56C2-4BFB-9305-20D4CC44CC52Q35903219-3DA304DB-A9CB-4EC8-98DA-69FE088189E7Q36393838-4FB611C2-4034-479A-8972-F2473E6EDF42Q36946451-F46850D6-79CA-49B7-B48E-AD7333D1ACD1Q38124531-1063B236-F5EB-4866-921A-8E538DDDF8DEQ38373653-2713C306-1078-485E-9C13-3ED87D74DE6DQ39878470-3E7ACBAE-63AD-4A30-A325-704E7C2BF52BQ42000646-B0209CE7-1593-4D77-B7F3-FAD112BEDD08Q42244127-23DCEE8B-E239-499E-9969-8BB01C2382C9Q43791060-01FD5D2A-9E87-4678-B695-3FA45C85C6A6Q45267960-B1F82FA4-FB47-400E-9E73-99CF300E4BB2Q46377143-8967998D-9DBF-4D9F-9635-28454FECD605Q46644550-3EDB8BFC-557B-4195-8B0B-A57DF2D1207DQ46666020-0E0E5118-F561-4387-BD7D-DB60AFF0D9AEQ46978096-69C9D6B5-927A-4AB7-9C2B-FAADB66FADF2Q48595483-8735231F-A1D0-43A7-87EB-3794307D0803Q51311524-A661B398-DC18-40B6-9682-C06E1DD03BDAQ51536809-18EC0F30-33F9-4920-A332-D576FB194BB2Q51942525-CBCDB3EB-9E1B-4BF1-9E42-B35CF0A0B9E5
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Cristian G. Bologa
@ast
Cristian G. Bologa
@en
Cristian G. Bologa
@es
Cristian G. Bologa
@sl
type
label
Cristian G. Bologa
@ast
Cristian G. Bologa
@en
Cristian G. Bologa
@es
Cristian G. Bologa
@sl
prefLabel
Cristian G. Bologa
@ast
Cristian G. Bologa
@en
Cristian G. Bologa
@es
Cristian G. Bologa
@sl
P1053
A-7952-2010
P106
P1153
6603290795
P21
P31
P3829
P496
0000-0003-2232-4244